Literature DB >> 23261411

Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer.

Larissa Mesquita Nunes1, Flávio Monteiro Ayres, Isadora Carvalho Medeiros Francescantonio, Vera Aparecida Saddi, Melissa Ameloti Gomes Avelino, Rita de Cássia Gonçalves Alencar, Rosana Correa da Silva, Alexandre J Meneghini, Isabela Jubé Wastowski.   

Abstract

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer and can present as lymph node metastasis in 30 to 65% of cases when initially diagnosed. High frequency recurrence, distant metastasis and treatment resistance can be found in cases of PTC so early diagnosis and treatment are critical for improved prognosis and better survival rates. The characterization of new biomarkers has proved useful for the diagnosis and follow-up of these patients. HLA-G is a non-classical HLA class I molecule whose expression in cancer cells has been associated with tumor evasion of immune response. Therefore, the aim of this study was to investigate the HLA-G expression and its clinical significance in PTC. Paraffin-embedded thyroid biopsies of 70 PTC patients (40 of whom had presented with metastasis) were evaluated. HLA-G-staining was observed in tumor cells in PTC, and the HLA-G expression was significantly associated with an increased occurrence of lymph node metastasis (p=0.0006) and capsular invasion (p=0.02). This preliminary data shows the HLA-G expression in thyroid carcinoma specimens for the first time and suggests that this expression could impair efficient anti-tumor immunity in PTC. This would indicate that HLA-G could have an independent prognostic value in PTC, principally for tumor recurrence.
Copyright © 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23261411     DOI: 10.1016/j.humimm.2012.12.012

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  14 in total

1.  BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.

Authors:  Trevor E Angell; Melissa G Lechner; Julie K Jang; Adrian J Correa; Jonathan S LoPresti; Alan L Epstein
Journal:  Thyroid       Date:  2014-07-15       Impact factor: 6.568

2.  HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer.

Authors:  Li Zhou; Zhe-Yu Niu; Zhi-Yong Liang; Wei-Xun Zhou; Lei You; Meng-Yi Wang; Lu-Tian Yao; Quan Liao; Yu-Pei Zhao
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

3.  RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Authors:  Robert C Smallridge; Ana-Maria Chindris; Yan W Asmann; John D Casler; Daniel J Serie; Honey V Reddi; Kendall W Cradic; Michael Rivera; Stefan K Grebe; Brian M Necela; Norman L Eberhardt; Jennifer M Carr; Bryan McIver; John A Copland; E Aubrey Thompson
Journal:  J Clin Endocrinol Metab       Date:  2013-12-02       Impact factor: 5.958

4.  Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

5.  Relationship between HLA-DRB1 gene polymorphism and breast cancer: A protocol for systematic review and meta-analysis.

Authors:  Linlin Liu; Xu Sun; Chenxi Yuan; Huaimin Liu
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

Review 6.  Immune response in thyroid cancer: widening the boundaries.

Authors:  Laura Sterian Ward
Journal:  Scientifica (Cairo)       Date:  2014-09-25

Review 7.  The Role of HLA-G Molecule and HLA-G Gene Polymorphisms in Tumors, Viral Hepatitis, and Parasitic Diseases.

Authors:  Fabrício C Dias; Erick C Castelli; Cristhianna V A Collares; Philippe Moreau; Eduardo A Donadi
Journal:  Front Immunol       Date:  2015-02-02       Impact factor: 7.561

Review 8.  Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

9.  Human leukocyte antigen-G expression and polymorphisms promote cancer development and guide cancer diagnosis/treatment.

Authors:  Yanwen Zhang; Shuwen Yu; Yali Han; Yunshan Wang; Yuping Sun
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

Review 10.  HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.